PT - JOURNAL ARTICLE AU - Lin, Gary AU - Strauss, Alexandra T. AU - Pinz, Maxwell AU - Martinez, Diego A. AU - Tseng, Katie K. AU - Schueller, Emily AU - Gatalo, Oliver AU - Yang, Yupeng AU - Levin, Simon A. AU - Klein, Eili Y. AU - For the CDC MInD-Healthcare Program TI - Explaining the “Bomb-Like” Dynamics of COVID-19 with Modeling and the Implications for Policy AID - 10.1101/2020.04.05.20054338 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.05.20054338 4099 - http://medrxiv.org/content/early/2020/04/07/2020.04.05.20054338.short 4100 - http://medrxiv.org/content/early/2020/04/07/2020.04.05.20054338.full AB - Using a Bayesian approach to epidemiological compartmental modeling, we demonstrate the “bomb-like” behavior of exponential growth in COVID-19 cases can be explained by transmission of asymptomatic and mild cases that are typically unreported at the beginning of pandemic events due to lower prevalence of testing. We studied the exponential phase of the pandemic in Italy, Spain, and South Korea, and found the R0 to be 2.56 (95% CrI, 2.41-2.71), 3.23 (95% CrI, 3.06-3.4), and 2.36 (95% CrI, 2.22-2.5) if we use Bayesian priors that assume a large portion of cases are not detected. Weaker priors regarding the detection rate resulted in R0 values of 9.22 (95% CrI, 9.01-9.43), 9.14 (95% CrI, 8.99-9.29), and 8.06 (95% CrI, 7.82-8.3) and assumes nearly 90% of infected patients are identified. Given the mounting evidence that potentially large fractions of the population are asymptomatic, the weaker priors that generate the high R0 values to fit the data required assumptions about the epidemiology of COVID-19 that do not fit with the biology, particularly regarding the timeframe that people remain infectious. Our results suggest that models of transmission assuming a relatively lower R0 value that do not consider a large number of asymptomatic cases can result in misunderstanding of the underlying dynamics, leading to poor policy decisions and outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Centers for Disease Control and Prevention (CDC) MInD-Healthcare Program (Grant Number 1U01CK000536). SL was supported by The National Science Foundation (CCF 1917819). DM was also supported by the Agency for Healthcare Research and Quality (AHRQ) Patient Safety Learning Laboratory program.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData derived from public domain resources https://github.com/CSSEGISandData/COVID-19